Transcriptomics

Dataset Information

4

Pharmacogenomics of IFNb therapy


ABSTRACT: This experiment set is used for the manuscript entitled: Pharmacogenomics of Interferon-b therapy in multiple sclerosis: Baseline IFN signature determines pharmacological differences between patients. In this study we generated and analyzed pre- and post- IFNb treatment gene expression patterns of RRMS patients with the aim of identifying pre-existing and/or drug-induced signatures that will allow us to make predictions on the expected pharmacological effects of IFNb treatment. We show that the expression level of IFN response genes prior to treatment, determines the pharmacological differences between patients with MS at the molecular level. A group of 16 Dutch patients (10 females and 6 males) with clinically definite relapsing-remitting MS was recruited from the outpatient clinic of the MS Centre Amsterdam. Mean age at start of IFNb therapy is 40.6 +/- 7.7, mean EDSS is 2.3 +/- 1.3 (range 1-6). Blood samples were obtained just before treatment and 1 month after start of the therapy. Patients received Avonex, Betaferon, Rebif 22 or Rebif 44. A compound treatment design type is where the response to administration of a compound or chemical (including biological compounds such as hormones) is assayed. Compound Based Treatment: Before and 1 month after IFNb therapy Keywords: compound_treatment_design Complex

ORGANISM(S): Homo sapiens  

SUBMITTER: Cornelis Verweij 

PROVIDER: E-GEOD-10655 | ArrayExpress | 2008-04-01

SECONDARY ACCESSION(S): GSE10655PRJNA107739

REPOSITORIES: GEO, ArrayExpress

altmetric image

Publications

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.

van Baarsen Lisa G M LG   Vosslamber Saskia S   Tijssen Marianne M   Baggen Josefien M C JM   van der Voort Laura F LF   Killestein Joep J   van der Pouw Kraan Tineke C T M TC   Polman Chris H CH   Verweij Cornelis L CL  

PloS one 20080402 4


BACKGROUND:Multiple sclerosis (MS) is a heterogeneous disease. In order to understand the partial responsiveness to IFNbeta in Relapsing Remitting MS (RRMS) we studied the pharmacological effects of IFNbeta therapy. METHODOLOGY:Large scale gene expression profiling was performed on peripheral blood of 16 RRMS patients at baseline and one month after the start of IFNbeta therapy. Differential gene expression was analyzed by Significance Analysis of Microarrays. Subsequent expression analyses on s  ...[more]

Similar Datasets

2010-06-24 | E-GEOD-15297 | ArrayExpress
2010-07-17 | E-GEOD-17167 | ArrayExpress
2010-06-25 | E-GEOD-15213 | ArrayExpress
2008-07-29 | E-GEOD-12094 | ArrayExpress
2010-06-23 | E-GEOD-16251 | ArrayExpress
2010-06-29 | E-GEOD-9821 | ArrayExpress
2010-06-24 | E-GEOD-13207 | ArrayExpress
2010-06-24 | E-GEOD-13206 | ArrayExpress
2009-01-05 | E-GEOD-11554 | ArrayExpress
2007-08-15 | E-GEOD-8770 | ArrayExpress